Article thumbnail
Location of Repository

Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration

By Mamdouh M Kabeel, Ashraf M El-Batarny, Mohamed K Tameesh and Moustafa A Abou El Enein
Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2698683
Provided by: PubMed Central

Suggested articles

Citations

  1. (2003). Benefi ts of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
  2. (2006). Bevacizumab Intraviteal (Avastin) for neovascular age-related macular degeneration.
  3. (2003). Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with vertiporfi n ocular photodynamic therapy.
  4. (2004). Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediate endothelial cell survival mechanisms.
  5. (2006). Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: a comparative study.
  6. (2006). Combined photodynamic therapy with verteporfi n and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
  7. Combined photodynamic therapy with verteporfi n and intravitreal triamcinolone acetonide for choroidal neovascularization.
  8. (2003). Concentric retinal pigment epithelium atrophy after single photodynamic therapy. Graefes Arch Clin Exp Opthtalmol,
  9. (2004). Evolving guidelines for intravitreal injections.
  10. (2003). Infl uence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium driven factor. Invest Opthtalmol Vis Sci,
  11. (1996). Inhibition of pre-retinal and optic nerve head neovascularization in pigs by itravitreal triamcinolone acetonide.
  12. (2006). Intravitreal Avastin: the low cost alternative to Lucentis?
  13. (2003). Intravitreal triamcinilone acetonide for exudative age related macular degeneration.
  14. (2001). Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol,
  15. (2004). Intravitreal Triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration.
  16. (2005). Optical coherence tomography fi ndings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging,
  17. (2002). Optical coherence tomography fi ndings following photodynamic therapy of choroidal neovascularization.
  18. (2004). Pegaptanib for neovascular age-related macular degeneration.
  19. (2005). Photodynamic therapy with verteporfi n combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.
  20. (2005). Randomized, controlled phase III of ranibizumab (Lucentis) for minimally classic or occult neovascular age-related macular degeneration. Presented at American Society of Retina Specialists Annual Meeting;
  21. (2006). Ranibizumab for neovascular age-related macular degeneration.
  22. (2006). Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
  23. (2006). Ranibizumab versus verteporfi n for neovascular age-related macular degeneration.
  24. (2006). Rationale for combination therapies for choroidal neovascularization.
  25. (2004). Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol,
  26. (2001). Theoretical investigation of the role of choriocapillaries blood fl ow in the treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration.
  27. (1999). Treatment of Age-Related Macular Degeneration With Photodynamic Therapy study group.
  28. (2006). VEGF-induced adult neovascularization: recrutement, retension, and role of accessory cells.
  29. (2001). Verteporfi n in Photodynamic Therapy Report 2.
  30. (2007). Verteporfi n therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.